TIDMAZN

RNS Number : 5565R

AstraZeneca PLC

30 June 2020

30 June 2020 15:00 BST

Transaction by Person Discharging Managerial Responsibilities

Disclosure under Article 19 of the EU Market Abuse Regulation

AstraZeneca PLC (the Company) announces that, on 29 June 2020, it was notified by Pascal Soriot, Chief Executive Officer, that, on 29 June 2020, Mr Soriot ceased to be beneficially interested in 127,389 Ordinary Shares of $0.25 each in the Company, following the gift of those shares to family members for nil consideration.

The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.

 
 1    Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                          Pascal Soriot 
     ----------------------------  ------------------------------------- 
 2    Reason for the notification 
     ------------------------------------------------------------------- 
 a)   Position/status               Chief Executive Officer 
     ----------------------------  ------------------------------------- 
 b)   Initial notification          Initial notification 
       /Amendment 
     ----------------------------  ------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------- 
 a)   Name                          AstraZeneca PLC 
     ----------------------------  ------------------------------------- 
 b)   LEI                           PY6ZZQWO2IZFZC3IOL08 
     ----------------------------  ------------------------------------- 
 4    Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ------------------------------------------------------------------- 
 a)   Description of the            Ordinary Shares of US$0.25 each in 
       financial instrument,         AstraZeneca PLC 
       type of instrument 
 
       Identification code           GB0009895292 
     ----------------------------  ------------------------------------- 
 b)   Nature of the transaction     Gift of shares to family members 
                                     for nil consideration 
     ----------------------------  ------------------------------------- 
 c)   Price(s) and volume(s)          Price(s)   Volume(s) 
                                              0     127,389 
                                                 ---------- 
     ----------------------------  ------------------------------------- 
 d)   Aggregated information        Not applicable - single transaction 
 
 
       - Aggregated volume 
 
 
       - Price 
     ----------------------------  ------------------------------------- 
 e)   Date of the transaction       29 June 2020 
     ----------------------------  ------------------------------------- 
 f)   Place of the transaction      Outside a trading venue 
     ----------------------------  ------------------------------------- 
 

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @ AstraZeneca .

Contacts

For details on how to contact the Investor Relations Team, please click here . For Media contacts, click here .

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHURUARRKUNOAR

(END) Dow Jones Newswires

June 30, 2020 10:00 ET (14:00 GMT)

Astrazeneca (LSE:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Astrazeneca Charts.